About
Avalo Therapeutics
AVTX.US
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc.
Profile
- Company Name
- Avalo Therapeutics, Inc.
- Market
- NasdaqCM
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- www.avalotx.com